Aqua Bio Technology ASA (Oslo Axess: ABT) recently announced its first quarter 2013 financial results. The Company continued its revenue build-up and posted an EBITDA of 3.9 million.
ABT’s revenues were NOK 7.2 million in the first quarter, against NOK 3.4 million in the previous quarter. In the first quarter of 2012 the Company had revenues of NOK 11.9 million, which included sign-on fees for major contracts.
The sales growth is reflected in the NOK 3.9 million EBITDA, which is up from an EBITDA of NOK 0.2 million the previous quarter. The first quarter of 2012 provided EBITDA of NOK 9.6 million.
Aqua Bio Technology ASA (ABT) develops, produces and markets patented ingredients and technologies to the international cosmetic and skin care industry. ABT’s ingredients Aquabeautine XL, Dermaclarine and Beauty Propelline are marine solutions derived from the hatching fluid of salmon, while Oceanx Oil in Serum is based on extract from seaweed.
ABT recently announced its 2012 financial results. The Company had its commercial breakthrough in 2012 and posted revenues of NOK 20.3 million for the year. ABT’s revenues the year before were NOK 0.5 million.
Contracts with two US based customers are the main reason for the commercial success. Aqua Bio Technology’s lead ingredient Aquabeautine XL™ is now included in new skincare products being widely marketed.
Aqua Bio Technology’s EBITDA for 2012 ended at NOK 8.0 million, compared to NOK -8.1 million in 2011. The company’s net result for the year was NOK 0.9 million, against NOK -13.5 the previous year.
For the fourth quarter alone, ABT posted revenues of NOK 3.4 million and an EBITDA of NOK 0.2 million. Net result for the fourth quarter was NOK -2.7 million.
The contracts secure ABT total revenues of more than NOK 120 million in the period 2012-2017, in the form of exclusivity and minimum royalty payments for Aquabeautine XL™. Product sales are expected to provide additional revenues.
Aqua Bio Technology ASA (Oslo Axess: ABT) today announced a partnership with Amway, one of the world’s largest direct sellers, for the use of ABT’s lead marine-derived ingredient Aquabeautine XL® in ARTISTRY® skincare products. ABT expects the agreement to provide revenues of at least NOK 8 million over the next 30 months, with a significant upside potential.
“The agreement with Amway is our most important commercial milestone to date. It confirms the potential of Aquabeautine XL® as a key component in the next generation of skincare products. Furthermore, our relationship with Amway will serve as an important reference as we roll out our new marketing strategy,” said ABT’s CEO Arvid Lindberg.
Michigan, US-based Amway is a worldwide leader in direct selling, with more than three million Independent Business Owners (IBOs) in more than 80 countries and territories around the world. Its ARTISTRY® is among the world’s top five, largest-selling, premium skincare brands.
Presperse Corporation is pleased to announce that they have entered into a distribution agreement with Aqua Bio Technologies ASA (ABT) based in Norway. ABT develops and produces patented ingredients and technologies based on extensive research and development.
Their novel marine active ingredients are derived from the pure and protected environment of Northern waters. ABT’s flagship ingredient, Aquabeautine XL™, is a patented marine solution that adds moistureand improves the renewal of skin cells in an effective and gentle manner. The first self-limiting enzyme of its kind, it is also proven to deliver anti-aging effects in vivo. 100% natural,biodegradable and sustainable, Aquabeautine XL™ is targeted for use in anti-aging products, spa/cosmeceutical products, as well as products for sensitive skin.
Aqua Bio Technology ASA (ABT) has entered into its third commercial distribution agreement in Asia for its flagship ingredient Aquabeautine XL™ (formerly known as Zonase X™) with Taiwanese company LICA Enterprises Group.
The agreement yields LICA Enterprises Group exclusivity on marketing and distribution of ABT’s products in Taiwan, China and Hong Kong.
This agreement allows ABT to complete its distribution network in the largest cosmetics markets globally. ABT’s strategy is to partner with leading distributors of cosmetic raw materials worldwide while maintaining its internal marketing focus. This yields ABT a greater degree of flexibility and strengthens the commercialization process of ABT’s patented ingredients in major target markets.